ReviewFrontiers in medical technology2021
Developing Antimicrobial Synergy With AMPs.
Review in Frontiers in medical technology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 90 citations in OpenAlex.
- Nano-antimicrobial peptides (Nano-AMPs) to combat resistant gram-negative bacteria.Drug delivery and translational research · 2026Review
- Cooperative membrane association as a mechanistic origin of synergistic antimicrobial peptide activity.RSC chemical biology · 2026Review
- Leishmanicidal Action of the Peptides 19-4LF, 19-2.5 and 19-2.5LF Topically Administered on Cutaneous Lesions Caused byPharmaceutics · 2026Article
- Antimicrobial Peptides as Next-Generation Disinfectants: Tackling Biocide and Antimicrobial Resistance in Hospital Hygiene - A Narrative Review.Probiotics and antimicrobial proteins · 2026Review
- Antimicrobial peptides isolated from probiotics as an alternative to antibiotics againstApplied and environmental microbiology · 2026Article
- Fever enhances host bacterial defence while limiting mitochondrial damage.Research square · 2026Article
- Recombinant Expression and Antimicrobial Mechanism of Cysteine-Rich Antimicrobial Peptides fromMarine drugs · 2026Article
- Cathelicidin-like Peptide for ResistantAntibiotics (Basel, Switzerland) · 2026Article
- The Importance of Ear Canal Microbiota and Earwax in the Prevention of Outer Ear Infections.International journal of molecular sciences · 2026Review
- The interactions between antimicrobial materials and bacterial membranes.Frontiers in chemistry · 2026Review
- Article
- Genome-Guided Identification and Characterisation of Broad-Spectrum Antimicrobial Compounds of Bacillus velezensis Strain PD9 Isolated from Stingless Bee Propolis.Probiotics and antimicrobial proteins · 2025Article
- Population-Level Dynamics and Community-Mediated Resistance to Antimicrobial Peptides.Biomolecules · 2025Review
- Exploring the Antimicrobial and Antiviral Properties of Cryptic Peptides from Human Fibrinogen.International journal of molecular sciences · 2025Article
- Current Status of the Application of Antimicrobial Peptides and Their Conjugated Derivatives.Molecules (Basel, Switzerland) · 2025Review
- Boosting AMPs' Power: From Structural Engineering to Nanotechnology-Based Delivery.Molecules (Basel, Switzerland) · 2025Review
- Combinatorial Effects of CPP-Modified Antimicrobial Peptides: Synergistic and Additive Interactions Against Pathogenic Bacteria.International journal of molecular sciences · 2025Article
- A biofilm-targeting lipo-peptoid to treatBiofilm · 2025Article
- Bactericidal activity of mammalian histones is caused by large membrane pore formation.Cell reports · 2025Article
- Advantages and Challenges of Using Antimicrobial Peptides in Synergism with Antibiotics for Treating Multidrug-Resistant Bacteria.ACS infectious diseases · 2025Review
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Antimicrobial peptides (AMPs) have been extensively studied due to their vast natural abundance and ability to kill microbes. In an era critically lacking in new antibiotics, manipulating AMPs for therapeutic application is a promising option. However, bacterial pathogens resistant to AMPs remain problematic. To improve AMPs antimicrobial efficacy, their use in conjunction with other antimicrobials has been proposed. How might this work? AMPs kill bacteria by forming pores in bacterial membranes or by inhibiting bacterial macromolecular functions. What remains unknown is the duration for which AMPs keep bacterial pores open, and the extent to which bacteria can recover by repairing these pores. In this mini-review, we discuss various antimicrobial synergies with AMPs. Such synergies might arise if the antimicrobial agents helped to keep bacterial pores open for longer periods of time, prevented pore repair, perturbed bacterial intracellular functions at greater levels, or performed other independent bacterial killing mechanisms. We first discuss combinations of AMPs, and then focus on histones, which have antimicrobial activity and co-localize with AMPs on lipid droplets and in neutrophil extracellular traps (NETs). Recent work has demonstrated that histones can enhance AMP-induced membrane permeation. It is possible that histones, histone fragments, and histone-like peptides could amplify the antimicrobial effects of AMPs, giving rise to antimicrobial synergy. If so, clarifying these mechanisms will thus improve our overall understanding of the antimicrobial processes and potentially contribute to improved drug design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.